
FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

## **INFORMATION DISCLOSURE CITATION**



ATTY. DOCKET NO. ON/4-32602A APPLICATION NO. 10/521,928 APPLICANT BHATNAGAR ET AL. FILING DATE JANUARY 21, 2005

Group

## **U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,617,307	10/14/86	Browne	514	300	06/20/84
	AB	4,687,767	08/18/87	Bosies et al.	514	89	07/26/85
	AC	4,749,713	06/07/88	Bowman et al.	514	341	03/07/86
	AD	4,777,163	10/11/88	Bosies et al.	514	80	07/24/87
	AE	4,939,130	07/03/90	Jaeggi et al.	514	94	02/27/89
	AF						
	AG						
	АН						
	Al						
	AJ						
	AK						
	AL						

## **FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
AM							
AN							
 AO							
 AP							
AQ							

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR		Combination with Tamoxifen Versus Tamoxifen Alone for all Women with Early Breast Cancer: First Results of the ATAC No. 9324, pp. 2131-2139 (2002).		
AS	*Conte et al., "Delay in Progression of Bone Metastases in Breast Cancer Patients Treated with Intravenous Pamidronate: Results from a Multinational Randomized Controlled Trial.", The Aredia Multinational Cooperative Group, <i>J Clin Oncol</i> , Vol. 14, No. 9, pp. 2552-2559 (1996).			
АТ	*Freyer, Ligneau and Trillet-Lenoir, "Palliative Hormone Therapy, Low-dose Chemotherapy, and Bisphosphonate in Breast Cancer Patients with Bone Marrow Involvement and Pancytopenia: Report of a Pilot Experience", <i>Eur J Intern Med</i> , Vol. 11, No. 6, pp. 329-333 (2000).			
EXAMINER		DATE CONSIDERED		

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

JAN 1 1 2006

ATTY. DOCKET NO. ON/4-32602A APPLICATION NO. 10/521,928 APPLICANT BHATNAGAR ET AL. FILING DATE JANUARY 21, 2005

Group

EXAMINER INITIAL (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Gasser et al., "Intravenous Administration of Zoledronic Acid Prevents the Bone Loss and Reduction of Mechanical Properties Induced by Aromatase Inhibition or Surgical Ovariectomy in Rats", St. Gallen Breast Cancer Meeting (March 2003) and Osaka, IBMS-JSBMR (June 2003).
	DB	Gnant et al., "Changes in Bone Mineral Density Caused by Anastrozole or Tamoxifen in Combination with Gosereline (± Zoledronate) as Adjuvant Treatment for Hormone Receptorpositive Premenopausal Breast Cancer: Results of a Randomized Multicenter Trial", Breast Cancer Research and Treatment, Contents Vol. 76, Suppl. 1, Abstract No. 12, p. S31 (2002).
	DC	*Harvey et al., "Issues Concerning the Role of Chemotherapy and Hormonal Therapy of Bone Metastases from Breast Carcinoma", <i>Cancer</i> , Vol. 80, Suppl. 8, pp. 1646-1651 (1997).
	DD	Hausmaninger, "Zoledronic Acid Prevents Bone Mineral Density Loss in Premenopausal Women Receiving Adjuvant Treatment for Hormone Receptor-positive Breast Cancer: Preliminary Results of a Randomized, Multicenter Trial of Zoledronic Acid in Patients Receiving Anastrozole or Tamoxifen in Combination with Goserelin", <i>The Breast, Primary Therapy of Early Breast Cancer</i> , 8 <sup>th</sup> Int. Conference, Vol. 12, Suppl. 1, Abstract P101, p. S43, (2003).
	DE	*Liersch et al., "Fernmetastasen Chirurgie beim Mammakarzinon", Viszeralchirurgie, Vol. 37, pp. 157-165 (2002).
	DF	Martindale, The Extra Pharmacopoeia, 31 <sup>st</sup> Edition, Reynolds, Ed., Royal Pharmaceutical Society, pp. 575, 781 and 782 (1996).
	DG	*Powles et al., "Breast Cancer Chemoprevention", <i>The Breast</i> , Vol. 10, pp. 58-61 (2001).
	DН	Ravdin, "Aromatase Inhibitors for the Endocrine Adjuvant Treatment of Breast Cancer", <i>Lancet</i> , Vol. 359, No. 9324, pp. 2126-2127 (2002).
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	
EXAMINER	₹	DATE CONSIDERED